Literature DB >> 3037013

Structural and immunological characterization of the intracellular forms of an abundant 68,000 Mr human cytomegalovirus protein.

W J Britt, L Vugler.   

Abstract

Murine monoclonal antibodies and polyvalent monospecific antisera reactive with an abundant 68,000 Mr (p68) human cytomegalovirus (CMV) virion protein were used to characterize this protein within CMV-infected cells. The protein was found to partition within the nucleus and cytoplasm of infected cells. Pulse-chase analysis indicated the p68 was degraded into three proteins of 52,000, 51,000 and 50,000 Mr which were found only within infected cells. Both cellular forms as well as the virion p68 were phosphorylated but non-glycosylated. The p68 was synthesized shortly after infection and in the presence of cytosine arabinoside, an inhibitor of viral DNA replication. Studies with monospecific antisera and a panel of monoclonal antibodies specific for the p68 suggested that this protein was not expressed on the surface of infectious virions or infected cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3037013     DOI: 10.1099/0022-1317-68-7-1897

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  23 in total

1.  Viable human cytomegalovirus recombinant virus with an internal deletion of the IE2 86 gene affects late stages of viral replication.

Authors:  Veronica Sanchez; Charles L Clark; Judy Y Yen; Roopashree Dwarakanath; Deborah H Spector
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Human cytomegalovirus nuclear and cytoplasmic dense bodies.

Authors:  B Severi; M P Landini; G Cenacchi; N Zini; N M Maraldi
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  Optimal replication of human cytomegalovirus correlates with endocytosis of glycoprotein gpUL132.

Authors:  Barbara Kropff; Yvonne Koedel; William Britt; Michael Mach
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

4.  Potential role for p53 in the permissive life cycle of human cytomegalovirus.

Authors:  N C Casavant; M H Luo; K Rosenke; T Winegardner; A Zurawska; E A Fortunato
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  Retrieval of human cytomegalovirus glycoprotein B from the infected cell surface for virus envelopment.

Authors:  K Radsak; M Eickmann; T Mockenhaupt; E Bogner; H Kern; A Eis-Hübinger; M Reschke
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

6.  Human cytomegaloviruses expressing yellow fluorescent fusion proteins--characterization and use in antiviral screening.

Authors:  Sarah Straschewski; Martin Warmer; Giada Frascaroli; Heinrich Hohenberg; Thomas Mertens; Michael Winkler
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

7.  The absence of p53 during Human Cytomegalovirus infection leads to decreased UL53 expression, disrupting UL50 localization to the inner nuclear membrane, and thereby inhibiting capsid nuclear egress.

Authors:  Man I Kuan; John M O'Dowd; Elizabeth A Fortunato
Journal:  Virology       Date:  2016-08-04       Impact factor: 3.616

8.  Polo-like kinase 1 as a target for human cytomegalovirus pp65 lower matrix protein.

Authors:  A Gallina; L Simoncini; S Garbelli; E Percivalle; G Pedrali-Noy; K S Lee; R L Erikson; B Plachter; G Gerna; G Milanesi
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  Analysis of the association of the human cytomegalovirus DNA polymerase subunit UL44 with the viral DNA replication factor UL84.

Authors:  Blair L Strang; Elisa Sinigalia; Laurie A Silva; Donald M Coen; Arianna Loregian
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

10.  Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.

Authors:  Zhongde Wang; Joy Martinez; Wendi Zhou; Corinna La Rosa; Tumul Srivastava; Anindya Dasgupta; Ravindra Rawal; Zhongqui Li; William J Britt; Don Diamond
Journal:  Vaccine       Date:  2009-12-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.